It also takes STING agonists as an example to illustrate the utilization and obstacles of lipid‐NPs in the field, underscoring the imperative for additional investigation to effectively regulate and refine the manipulation of these NPs for improved cancer immunotherapy. This evidence concerns the gene STING1 and cancer.